EUVIMEDEUVIMED entdecken
Crossref

Molecular and Computational Platforms for Cancer Drug Screening and Precision Therapy

Matthews, Jonathan Martin

Knowledge@UChicago (University of Chicago) · 01.06.2023

DOI: 10.6082/dznch-a3q92 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Knowledge@UChicago (University of Chicago), erschienen am 01.06.2023. Verfasst von Matthews und 1 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pharmacological cancer therapy can lead to a range of outcomes, even among patients with cancer in the same location, originating from same cell type, and with the same biomolecular markers. Treatment heterogeneity is also reflected at the cellular level, where cells within an individual tumor can exhibit discordant responses to a drug. This fractal nature of cancer diversity has encouraged the development of hundreds of unique drugs and therapeutic regimens, with the ambition of matching each patient to an ideal treatment option. The rich space of possible treatments is infeasible to study en masse through clinical trials, motivating the use of disease models to screen and hone in on promising candidates. Drug screening must not only explore the large treatment space, but also extract rich measurements for each condition to reflect nuanced pathophysiological processes. These two aspects often pull experimental designs in opposite directions, constraining assays to explore few conditions in detail (high-content analysis) or many conditions superficially (high-throughput screening). Here, I describe the development, validation, and exploration of three technologies for high-throughput and high-content drug screening. The first is a deep learning-powered software tool, OrganoID, that analyzes microscopy images of patient-derived cancer organoids to follow changes in organoid number, size, and shape in response to drug exposure. The second technology, PicoScreen, enables computer-controlled screening of reagent combinations in picoliter droplets with microscopy. Finally, in Screen-seq, a novel molecular barcoding and microfluidic strategy measures transcriptomic responses of thousands of individual cells to all possible combinations of multiple reagents under study. These technologies aim to make screening methods more efficient, comprehensive, and information-rich, to expand our understanding of disease processes, such as cancer, and improve treatment options and selection for patients.

Schlagwörter

anticancer drug screeningprecision oncologypatient-derived cancer organoidshigh-content screeninghigh-throughput screeningdeep learning image analysisorganoidsDNA barcodingmicrofluidicstranscriptomic response

Zitieren

APA

Matthews, & Martin, J. (2023). Molecular and Computational Platforms for Cancer Drug Screening and Precision Therapy. Knowledge@UChicago (University of Chicago). https://doi.org/10.6082/dznch-a3q92

Vancouver

Matthews, Martin J. Molecular and Computational Platforms for Cancer Drug Screening and Precision Therapy. Knowledge@UChicago (University of Chicago). 2023. doi:10.6082/dznch-a3q92

BibTeX
@article{Matthews2023,
  author = {Matthews and Martin, Jonathan},
  title = {Molecular and Computational Platforms for Cancer Drug Screening and Precision Therapy},
  journal = {Knowledge@UChicago (University of Chicago)},
  year = {2023},
  doi = {10.6082/dznch-a3q92}
}
Kostenlos starten →